| 000 | 01912 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250518060614.0 | ||
| 264 | 0 | _c20200529 | |
| 008 | 202005s 0 0 eng d | ||
| 022 | _a1879-260X | ||
| 024 | 7 |
_a10.1016/j.bbadis.2019.165552 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAbe, Koki | |
| 245 | 0 | 0 |
_amTORC1 inhibition attenuates necroptosis through RIP1 inhibition-mediated TFEB activation. _h[electronic resource] |
| 260 |
_bBiochimica et biophysica acta. Molecular basis of disease _c12 2019 |
||
| 300 |
_a165552 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAutophagy _xdrug effects |
| 650 | 0 | 4 |
_aBasic Helix-Loop-Helix Leucine Zipper Transcription Factors _xmetabolism |
| 650 | 0 | 4 |
_aCardiotonic Agents _xpharmacology |
| 650 | 0 | 4 | _aCell Line |
| 650 | 0 | 4 |
_aMechanistic Target of Rapamycin Complex 1 _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aMyocytes, Cardiac _xcytology |
| 650 | 0 | 4 |
_aNecroptosis _xdrug effects |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aProtein Serine-Threonine Kinases _xmetabolism |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aReceptor-Interacting Protein Serine-Threonine Kinases |
| 650 | 0 | 4 |
_aSirolimus _xpharmacology |
| 700 | 1 | _aYano, Toshiyuki | |
| 700 | 1 | _aTanno, Masaya | |
| 700 | 1 | _aMiki, Takayuki | |
| 700 | 1 | _aKuno, Atsushi | |
| 700 | 1 | _aSato, Tatsuya | |
| 700 | 1 | _aKouzu, Hidemichi | |
| 700 | 1 | _aNakata, Kei | |
| 700 | 1 | _aOhwada, Wataru | |
| 700 | 1 | _aKimura, Yukishige | |
| 700 | 1 | _aSugawara, Hirohito | |
| 700 | 1 | _aShibata, Satoru | |
| 700 | 1 | _aIgaki, Yusuke | |
| 700 | 1 | _aIno, Shoya | |
| 700 | 1 | _aMiura, Tetsuji | |
| 773 | 0 |
_tBiochimica et biophysica acta. Molecular basis of disease _gvol. 1865 _gno. 12 _gp. 165552 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.bbadis.2019.165552 _zAvailable from publisher's website |
| 999 |
_c30090537 _d30090537 |
||